Pediatrix Medical Group (NYSE:MD) Stock Crosses Above 200 Day Moving Average – Should You Sell?

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $18.37 and traded as high as $22.47. Pediatrix Medical Group shares last traded at $22.24, with a volume of 450,218 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms have commented on MD. UBS Group lifted their target price on Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Zacks Research upgraded Pediatrix Medical Group from a “hold” rating to a “strong-buy” rating in a report on Friday, November 21st. Wall Street Zen raised Pediatrix Medical Group from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 4th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. Finally, Truist Financial lifted their price target on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Pediatrix Medical Group currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Pediatrix Medical Group Stock Performance

The company has a market cap of $1.91 billion, a P/E ratio of 11.71 and a beta of 0.73. The company has a quick ratio of 1.83, a current ratio of 1.83 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $22.43 and a two-hundred day simple moving average of $18.37.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.46 by $0.21. The firm had revenue of $492.88 million during the quarter, compared to analyst estimates of $476.45 million. Pediatrix Medical Group had a net margin of 8.44% and a return on equity of 20.45%. The business’s revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.44 EPS. On average, sell-side analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 EPS for the current year.

Insider Transactions at Pediatrix Medical Group

In related news, CEO Mark S. Ordan sold 23,000 shares of Pediatrix Medical Group stock in a transaction on Monday, December 15th. The stock was sold at an average price of $22.41, for a total transaction of $515,430.00. Following the transaction, the chief executive officer directly owned 302,805 shares in the company, valued at approximately $6,785,860.05. The trade was a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Laura A. Linynsky sold 10,000 shares of the business’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $21.65, for a total value of $216,500.00. Following the sale, the director directly owned 32,232 shares of the company’s stock, valued at $697,822.80. This represents a 23.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 43,478 shares of company stock worth $972,924 in the last 90 days. 0.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in MD. Blue Trust Inc. purchased a new stake in Pediatrix Medical Group in the 4th quarter worth approximately $37,000. Canada Pension Plan Investment Board purchased a new position in Pediatrix Medical Group during the second quarter valued at approximately $83,000. Quantbot Technologies LP bought a new position in shares of Pediatrix Medical Group in the second quarter worth approximately $99,000. Smartleaf Asset Management LLC boosted its position in shares of Pediatrix Medical Group by 10.6% in the third quarter. Smartleaf Asset Management LLC now owns 6,250 shares of the company’s stock worth $101,000 after purchasing an additional 601 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in shares of Pediatrix Medical Group by 219.3% in the second quarter. Tower Research Capital LLC TRC now owns 7,685 shares of the company’s stock worth $110,000 after purchasing an additional 5,278 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.